
The White House is weighing whether to abandon its nominee to lead the Food and Drug Administration, Heidi Overton, just days before a Senate committee vote that could decide her fate. Some Trump administration officials doubt the Senate will confirm Overton, and are discussing whether to shore up her nomination or drop it, The Washington Post reported on Monday.
The Washington Post reported on Monday, November 16, 2026, that some Trump administration officials are growing sceptical that the Senate will confirm Heidi Overton as commissioner of the Food and Drug Administration. The report, citing four people familiar with the matter, said officials are weighing two options: a last effort to save the nomination, or abandoning it before the Senate Health, Education, Labor and Pensions Committee votes on Wednesday. The report made it one of the week's most closely watched confirmation fights.
Overton, a board-certified physician and deputy director of the White House Domestic Policy Council, was nominated by President Donald Trump in August. The FDA commissioner post has been vacant since Marty Makary resigned in May, leaving the agency without a Senate-confirmed leader for six months. The arithmetic is unforgiving: the committee has 21 members, she needs 11 votes to advance, and Republicans hold a one-seat majority, so one Republican defection would sink her if every Democrat votes against her.
The Food and Drug Administration is one of the most consequential agencies in American life. It decides which medicines and vaccines reach the market and sets the rules for food safety. Its commissioner shapes decisions that affect every household. A vacancy at the top, stretching now to half a year, leaves those decisions to acting officials as the administration overhauls federal health policy under Health Secretary Robert F. Kennedy Jr.
Overton's nomination was controversial from the start, and the opposition has come from several directions at once. Some Republicans have raised concerns, many Democrats oppose her, and prominent supporters of Kennedy's Make America Healthy Again (MAHA) movement have also lined up against her. The objections centre on three issues: vaccines, the abortion pill mifepristone, and intrauterine devices, or IUDs. The FDA is due to complete a safety review of mifepristone in March.
Wednesday's vote will be the first formal test of whether Overton can survive a committee where the president's party holds only a single-vote advantage. If she clears the panel, she would still need a majority on the Senate floor. If she fails in committee, her nomination would effectively be over, and the White House would have to start again with a new pick.
The timing adds pressure on both sides. Democrats retake the Senate in January, after their victories in the November 3 midterm elections. If Overton is not confirmed by then, her nomination would likely be returned to the White House, and face a Democratic majority even less inclined to confirm her. Wednesday's vote is close to a now-or-never moment: either the White House finds the votes in the coming days, or the nomination is likely finished.
The clearest public signal so far has come from committee chairman Bill Cassidy himself. On CBS's "Face the Nation" on Sunday, he said he still had "questions" about Overton's fitness to serve. Asked about the outcome of Wednesday's vote, he was blunt: "I cannot tell you the outcome of that vote right now." The remarks stopped well short of an endorsement.
The White House has not publicly said whether it intends to fight for Overton or withdraw her. The Post's report describes officials divided between shoring up the nomination and abandoning it. Overton's critics, meanwhile, have made their case in public. The "Heidi Vaperton" campaign that launched on Friday uses posters and yard signs to urge senators to reject her, as MAHA supporters argue that her record on vaccines, mifepristone and IUDs disqualifies her.
The fight over Heidi Overton is about more than one nomination. The FDA commissioner decides how quickly new medicines reach patients, how rigorously vaccines and food are scrutinised, and how the agency handles some of the most contested questions in American health policy. Whoever leads the agency will shape those decisions for years, and a prolonged vacancy leaves them to acting officials without Senate-confirmed authority. The nomination also tests the balance of power inside the administration's health agenda: Kennedy's MAHA movement has driven the overhaul of federal health policy, and its supporters' opposition to Overton shows the movement can also block the president's own picks when it disagrees with them.
All eyes are now on the Senate Health, Education, Labor and Pensions Committee vote on Wednesday, November 18. If Overton wins the 11 votes she needs, her nomination moves to the full Senate, where a final confirmation vote would follow. If she falls short, the White House will have to decide quickly whether to name a replacement or leave the FDA under acting leadership into the new year. Whatever happens, the result will be read as a verdict not only on one nominee, but on the administration's grip on its own health agenda in the final weeks of Republican control of the Senate.
Who is Heidi Overton?
Heidi Overton is a board-certified physician and deputy director of the White House Domestic Policy Council, nominated by President Trump in August 2026 to lead the FDA.
Why is her nomination in trouble?
She faces opposition from some Republicans, many Democrats and prominent supporters of the Make America Healthy Again movement, over vaccines, the abortion pill mifepristone and IUDs.
When is the committee vote?
The Senate Health, Education, Labor and Pensions Committee is set to vote on her nomination on Wednesday, November 18, 2026.
What happens if she is not confirmed?
Democrats retake the Senate in January, so her nomination would likely be returned to the White House if she is not confirmed by then.
How long has the FDA been without a commissioner?
Since Marty Makary resigned in May 2026 — six months without a Senate-confirmed leader.
Related coverage: US measles cases have surged past 7,700 with 13 deaths reported in 2026 — read the full report. Scientists have also revealed that the CDC blocked a measles alert for pregnant women — read more.